胰岛素信号及其应用
Thi Kim Chung Le1, Xuan Dat Dao1, Dang Vung Nguyen1
1School of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Vietnam.
Frontiers in endocrinology
|September 4, 2023
概括
胰岛素耐药性研究已经推进了疾病的诊断和治疗. 本综述综合了关于胰岛素信号传导,抗性机制以及肥胖和阿尔茨海默病等相关疾病的最新发现.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 代谢疾病 代谢疾病
背景情况:
- 胰岛素的发现彻底改变了糖尿病治疗,并刺激了对胰岛素活性和抗性的研究.
- 了解胰岛素信号传递对于解决代谢障碍至关重要.
- 胰岛素耐药性与日益增长的慢性疾病名单有关.
研究的目的:
- 综合有关胰岛素信号和抗胰岛素机制的最新发现.
- 探索胰岛素作用的生理基础和胰岛素抵抗的病理生理学.
- 讨论针对胰岛素抵抗的当前应用和潜在的治疗策略.
主要方法:
- 关于胰岛素信号通路的当前文献的综述.
- 对后受体缺陷的分析有助于胰岛素抵抗.
- 综合最近关于与胰岛素抵抗相关的疾病的发现.
主要成果:
- 详细描述从受体到下游效应的胰岛素信号通路.
- 对胰岛素抵抗背后的后受体机制的分析.
- 确定与胰岛素抵抗相关的关键疾病,包括肥胖,心血管疾病,阿尔茨海默病和癌症.
结论:
- 对胰岛素抵抗机制的最新理解可以为新的治疗方法提供信息.
- 针对胰岛素抵抗路径提供了治疗相关慢性疾病的潜力.
- 持续的研究对于开发有效的干预措施来治疗与胰岛素抵抗相关的疾病至关重要.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Insulin: Biosynthesis, Chemistry, and Preparation
424
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
424
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358


